Illinois secures AbbVie’s $195 million investment for North Chicago facility

CHICAGO, Ill. (WTVO) — AbbVie, the maker of Botox, Humira, and Rinvoq, will invest $195 million to expand its manufacturing facility in Illinois.

The company discovers, develops, and commercializes therapies for health issues in areas such as immunology, oncology, neuroscience, eye care, and aesthetics. An offshoot of Abbott Laboratories, it is known for products such as Humira, Rinvoq, and Botox.

Illinois Gov. JB Pritzker and representatives from the company announced the expansion to its North Chicago facility on Tuesday.

​“AbbVie’s decision to expand its manufacturing footprint in Illinois is a testament to our state’s world-class workforce, infrastructure, cutting-edge research institutions, and location that keeps businesses connected to the nation and the world,” said Pritzker. “As a global leader in pharmaceuticals, AbbVie’s investment in Illinois bolsters our world-class biomanufacturing ecosystem and creates jobs while it innovates next generation medicines.”

The company has committed to investing more than $10 million in U.S. capital projects over the next decade.

The North Chicago manufacturing facility employs more than 11,000 people.

​“Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.”

With an agreement under Illinois’ Economic Growth Plan, AbbVie committed to creating at least 50 new jobs within the next three years.